Researchers determine how sleep duration, sleep debt, and shift work impact the risk of infections among Norwegian nurses.
US FDA grants breakthrough therapy status for Nuvalent’s NVL-655
NVL-655 is intended to treat locally advanced or metastatic ALK-positive NSCLC patients previously treated with two or more ALK TKIs. Credit: Sebastian Kaulitzki / Shutterstock.com.